Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,913 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murata N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N. Fujisawa Y, et al. Among authors: ishikawa m. J Dermatol Sci. 2019 May;94(2):284-289. doi: 10.1016/j.jdermsci.2019.04.003. Epub 2019 Apr 17. J Dermatol Sci. 2019. PMID: 31023613
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma.
Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murao N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N. Fujisawa Y, et al. Among authors: ishikawa m. Cancer Med. 2019 May;8(5):2146-2156. doi: 10.1002/cam4.2110. Epub 2019 Apr 1. Cancer Med. 2019. PMID: 30932370 Free PMC article.
Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN).
Kamimura A, Nakamura Y, Takenouchi T, Matsushita S, Omodaka T, Yamamura K, Uchi H, Yoshikawa S, Yanagisawa H, Ito T, Kiyohara Y, Nakamura Y, Aoki M, Ishizuki S, Oashi K, Miyagawa T, Maeda T, Ogata D, Hatta N, Ohe S, Isei T, Takahashi A, Umeda Y, Yamaguchi B, Ishikawa M, Horimoto K, Fujsawa Y, Uehara J, Shibayama Y, Kiniwa Y, Kawahara Y, Matsuya T, Uhara H, Kato J, Nakamura Y, Murakami T, Namikawa K, Yoshino K, Funakoshi T, Takatsuka S, Matsui Y, Sasaki J, Koga H, Yokota K, Komori T, Fukushima S, Yamazaki N. Kamimura A, et al. Among authors: ishikawa m. J Dermatol. 2022 Sep;49(9):837-844. doi: 10.1111/1346-8138.16422. Epub 2022 May 5. J Dermatol. 2022. PMID: 35510662
Narrower clinical margin in high or very high-risk squamous cell carcinoma: a retrospective, multicenter study of 1,000 patients.
Baba N, Kato H, Nakamura M, Matsushita S, Aoki M, Fujimoto N, Kato T, Iino S, Saito S, Yasuda M, Asai J, Ishikawa M, Yatsushiro H, Kawahara Y, Matsuya T, Araki R, Teramoto Y, Hasegawa M, Tokunaga T, Nakamura Y. Baba N, et al. Among authors: ishikawa m. J Dtsch Dermatol Ges. 2022 Aug;20(8):1088-1099. doi: 10.1111/ddg.14810. Epub 2022 Aug 4. J Dtsch Dermatol Ges. 2022. PMID: 35927033
Knapperer Resektionsrand bei Plattenepithelkarzinomen mit hohem oder sehr hohem Risiko: eine retrospektive multizentrische Studie mit 1000 Patienten.
Baba N, Kato H, Nakamura M, Matsushita S, Aoki M, Fujimoto N, Kato T, Iino S, Saito S, Yasuda M, Asai J, Ishikawa M, Yatsushiro H, Kawahara Y, Matsuya T, Araki R, Teramoto Y, Hasegawa M, Tokunaga T, Nakamura Y. Baba N, et al. Among authors: ishikawa m. J Dtsch Dermatol Ges. 2022 Aug;20(8):1088-1100. doi: 10.1111/ddg.14810_g. J Dtsch Dermatol Ges. 2022. PMID: 35971579
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A, Morita S, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K. Ooki A, et al. Among authors: ishikawa m. Cancer Med. 2020 Mar;9(5):1779-1789. doi: 10.1002/cam4.2826. Epub 2020 Jan 21. Cancer Med. 2020. PMID: 31962002 Free PMC article. Clinical Trial.
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.
Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K. Iwamoto S, et al. Among authors: ishikawa m. Cancer Med. 2018 Sep;7(9):4217-4227. doi: 10.1002/cam4.1623. Epub 2018 Jul 26. Cancer Med. 2018. PMID: 30051609 Free PMC article. Clinical Trial.
3,913 results